FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease

Renzo Mignani, Federico Pieruzzi, Francesco Berri, Alessandro Burlina, Benito Chinea, Maurizio Gallieni, Maurizio Pieroni, Alessandro Salviati, Marco Spada, Renzo Mignani, Federico Pieruzzi, Francesco Berri, Alessandro Burlina, Benito Chinea, Maurizio Gallieni, Maurizio Pieroni, Alessandro Salviati, Marco Spada

Abstract

Two disease severity scoring systems, the Mainz Severity Score Index (MSSI) and Fabry Disease Severity Scoring System (DS3), have been validated for quantifying the disease burden of Fabry disease. We aimed to develop a dynamic mathematical model [the FASTEX (FAbry STabilization indEX)] to assess the clinical stability. A multidisciplinary panel of experts in Fabry disease first defined a novel score of severity [raw score (RS)] based on three domains with a small number items in each domain (nervous system domain: pain, cerebrovascular events; renal domain: proteinuria, glomerular filtration rate; cardiac domain: echocardiography parameters, electrocardiograph parameters and New York Heart Association class) and evaluated the clinical stability over time. The RS was tested in 28 patients (15 males, 13 females) with the classic form of Fabry disease. There was good statistical correlation between the newly established RS and a weighted score (WS), with DS3 and MSSI (R (2) = 0.914, 0.949, 0.910 and 0.938, respectively). In order to refine the RS further, a WS, which was expressed as a percentage value, was calculated. This was based on the relative clinical significance of each item within the domain with the panel agreeing on the attribution of a different weight of clinical damage to a specific organ system. To test the variation of the clinical burden over time, the RS was repeated after 1 year. The panel agreed on a cut-off of a 20% change from baseline as the clinical WS to define clinical stability. The FASTEX model showed good correlation with the clinical assessment and with clinical variation over time in all patients.

Keywords: Fabry disease; disease progression; disease stability; organ dysfunction scores; α-galactosidase A/α-galactosidase A deficiency.

Figures

Fig. 1.
Fig. 1.
(A) Percentage severity of single domains and total severity score. (B) Total percentages of severity for single domains and total severity score at first and second visit calculated by applying the algorithm.
Fig. 2.
Fig. 2.
(A) Percentage severity of single domains and total severity score. (B) Total percentages of severity for single domains and total severity score at first and second visit calculated by applying the algorithm.
Fig. 3.
Fig. 3.
(A) Percentage severity of single domains and total severity score. (B) Total percentages of severity for single domains and total severity score at first and second visit calculated by applying the algorithm.

References

    1. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). , Vol. 3, 8th edn New York: McGraw-Hill, 2001, 3733–3774
    1. Germain DP. Fabry disease. 2010; 5: 30
    1. Laney DA, Peck DS, Atherton AM et al. . Fabry disease in infancy and early childhood: a systematic literature review. 2014. 5; 17: 323–330
    1. Mehta A, Clarke JT, Giugliani R et al. . Natural course of Fabry disease: changing pattern of causes of death in FOS—Fabry Outcome Survey. 2009; 46: 548−552
    1. Waldek S, Patel MR, Banikazemi M et al. . Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. 2009; 11: 790−796
    1. Nakao S, Takenaka T, Maeda M et al. . An atypical variant of Fabry's disease in men with left ventricular hypertrophy. 1995; 333: 288–293
    1. Sachdev B, Takenaka T, Teraguchi H et al. . Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. 2002; 105: 1407–1411
    1. Wilcox WR, Oliveira JP, Hopkin RJ et al. . Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. 2008; 93: 112−128
    1. Deegan PB, Baehner AF, Barba Romero MA et al. . Natural history of Fabry disease in females in the Fabry Outcome Survey. 2006; 43: 347–352
    1. Lyon M. Gene activation in the X-chromosome of the mouse. 1961; 190: 372−373
    1. Eng CM, German DP, Banikazemi M et al. . Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. 2006; 8: 539−548
    1. Schiffmann R, Kopp JB, Austin HA III et al. . Enzyme replacement therapy in Fabry disease: a randomized controlled trial. 2001; 285: 2743−2749
    1. Eng CM, Guffon N, Wilcox WR et al. . Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry's disease. 2001; 345: 9−16
    1. Giannini EH, Mehta AB, Hilz MJ et al. . A validated disease severity scoring system for Fabry disease. 2009; 99: 289−290
    1. Whybra C, Kampmann C, Krummenauer F et al. . The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy. 2004; 65: 299−307
    1. Hughes DA, Ramaswami U, Barba Romero MÁ et al. . Age adjusting severity scores for Anderson-Fabry Disease. 2010; 101: 219−227
    1. Delbecq AL, van de Ven AH, Gustafson DH. Guidelines for conducting nominal group technique meetings. In: Delbecq AL, van de Ven AH, Gustafson DH (eds). . Middleton, WI:Greenbriar Press, 1986
    1. Likert RA. A technique for the measurement of attitudes. 1932; 140: 5−55
    1. Rombach SM, Smid BE, Linthorst GE et al. . Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. 2014; 37: 341−352
    1. Mehta A, Beck M, Eyskens F et al. . Fabry disease: a review of current management strategies. 2010; 103: 641–659

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren